Aneurysmal Subarachnoid Hemorrhage and Superior Mesenteric Artery Flow Study

University of Florida14 enrolled

Overview

The purpose of this research study is to determine if the diameter and flow of the superior mesenteric artery in patients with aneurysmal subarachnoid hemorrhage undergoing hypertensive therapy for cerebral artery vasospasm are effected enough to justify withholding enteral nutrition.

Study measurements of the diameter and Doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) in patients undergoing hypertensive therapy for cerebral vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH), to justify the withholding of enteral nutrition.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Intracranial Aneurysm

Interventions

UltrasoundDEVICE

Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient diagnosed with aSAH Exclusion Criteria: * Hemodynamic instability * Already receiving vasopressor therapy * Non-aneurysmal SAH * Intracranial hemorrhage of other cause * Not anticipated to receive hypertensive therapy with vasoactive medications for cerebral vasospasm from SAH or suspected aSAH * Unable to visualize SMA using ultrasound * Pregnancy

Locations (1)

UF Health

Gainesville, Florida, United States

Outcomes

Primary Outcomes

Change between baseline and 21 days of abdominal ultrasound measurement of the diameter in the superior mesenteric artery

Time frame: Change from baseline up to 21 days

Change between baseline and 21 days of abdominal ultrasound measurement of the doppler flow velocity in the superior mesenteric artery

Time frame: Change from baseline up to 21 days

Secondary Outcomes

Number of participants with non-occlusive mesenteric ischemia (NOMI)

Number of participants with non-occlusive mesenteric ischemia (NOMI) undergoing hypertension therapy with vasoactive medications for cerebral arterial vasospasm in aneurysmal subarachnoid hemorrhage (aSAH).

Time frame: Change from baseline up to 21 days

Number of participants with non occlusive bowel necrosis (NOBN)

Number of participants with non occlusive bowel necrosis (NOBN) undergoing hypertension therapy with vasoactive medications for cerebral arterial vasospasm in aneurysmal subarachnoid hemorrhage (aSAH).

Time frame: Change from baseline up to 21 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.